Author:
Kenji Sakai J Gastro Abst Vol 37 Issue 2 (2002) pp 112-118
|
[
Next Thread |
Previous Thread |
Next Message |
Previous Message
]
Date Posted: Wed, March 20 2002, 9:10:48 PST
Journal of Gastroenterology
ISSN: 0944-1174 (printed version)
ISSN: 1435-5922 (electronic version)
Table of Contents
Abstract Volume 37 Issue 2 (2002) pp 112-118
DOI 10.1007/s005350200005
Propranolol ameliorates thrombocytopenia in patients with cirrhosis
Kenji Sakai (1), Tadashi Iwao (2), Kazuhiko Oho (1), Atsushi Toyonaga (1), Michio Sata (1)
(1) Second Department of Medicine, Division of Gastroenterology and Endoscopy, Kurume University School of Medicine, 67 Asahi, Kurume 830-0011, Japan
(2) Iwao Hospital, Department of Medicine, Hita, Japan
Received: February 22, 2001 / Accepted: August 24, 2001
Background. Propranolol causes splanchnic arterial vasoconstriction owing to the unopposed alpha vasoconstriction resulting from the blockade of beta-2 adrenoceptors. It is therefore hypothesized that this drug may cause vasoconstriction in the splenic arterial circulation and, thus, modify the manifestations of hypersplenism, such as thrombocytopenia. The aim of the present study was to test this hypothesis. Methods. Nineteen patients with cirrhosis and thrombocytopenia (fewer than thrombocytes 7 × 104/mm3) were include. The subjects of the study. All of them were studied in the morning after an overnight fast. To evaluate splenic arterial hemodynamics, the pulsatility index was measured by Doppler ultrasonography. Platelet counts and platelet-associated immunoglobulin G levels were also recorded. The subjects were then randomized to receive propranolol (n = 10) or placebo (n = 9). The measurements were repeated after 1 week of propranolol or placebo administration. The dose of propranolol was determined so that a 20% to 25% reduction in heart rate was achieved. Results. Placebo administration caused no significant changes in splenic artery hemodynamics. In contrast, propranolol administration significantly increased the intra splenic artery pulsatility index (from 1.10 ± 0.06 to 1.24 ± 0.08; P < 0.01). Placebo administration caused no significant changes in the platelet count. In contrast, propranolol administration significantly increased the platelet count (from 4.5 ± 0.3 to 6.1 ± 0.73 × 104/mm3; P < 0.05). Furthermore, the change in platelet count was significantly correlated with either the change in extrasplenic artery pulsatility index (r = 0.78, P < 0.05) or the change in intrasplenic artery pulsatility index (r = 0.78, P < 0.01). Platelet-associated immunoglobulin G levels were not modified in either of the two groups. Conclusions. Propranolol ameliorates thrombocytopenia in patients with cirrhosis. This effect may be caused mainly by hemodynamic changes in the spleen, rather than being caused by immunological mechanisms.
[
Next Thread |
Previous Thread |
Next Message |
Previous Message
]
|
